QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
NASDAQ:VYGR

Voyager Therapeutics (VYGR) Stock Price, News & Analysis

$9.64
+0.20 (+2.12%)
(As of 03/4/2024 ET)
Today's Range
$9.19
$9.68
50-Day Range
$7.15
$10.84
52-Week Range
$6.06
$14.34
Volume
1.12 million shs
Average Volume
1.07 million shs
Market Capitalization
$523.45 million
P/E Ratio
3.12
Dividend Yield
N/A
Price Target
$16.00

Voyager Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
66.0% Upside
$16.00 Price Target
Short Interest
Bearish
5.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.97
Upright™ Environmental Score
News Sentiment
0.58mentions of Voyager Therapeutics in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$27,272 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.91) to ($1.35) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.43 out of 5 stars

Medical Sector

136th out of 948 stocks

Biological Products, Except Diagnostic Industry

16th out of 157 stocks


VYGR stock logo

About Voyager Therapeutics Stock (NASDAQ:VYGR)

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

VYGR Stock Price History

VYGR Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Voyager Therapeutics Inc (VT6.BE)
Voyager Therapeutics: Q4 Earnings Insights
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Q4 2023 Voyager Therapeutics Inc Earnings Call
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Voyager Therapeutics (VYGR) to Release Earnings on Wednesday
VYGR Mar 2024 7.500 call
VYGR Mar 2024 7.500 put
See More Headlines
Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/04/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:VYGR
Fax
N/A
Employees
125
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$18.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+66.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$132.33 million
Pretax Margin
53.49%

Debt

Sales & Book Value

Annual Sales
$250.01 million
Cash Flow
$3.09 per share
Book Value
$5.37 per share

Miscellaneous

Free Float
51,749,000
Market Cap
$523.45 million
Optionable
Optionable
Beta
0.96
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Alfred W. Sandrock Jr. (Age 66)
    M.D., Ph.D., President, CEO & Director
    Comp: $825.41k
  • Mr. Peter P. Pfreundschuh CPA (Age 55)
    Chief Financial Officer
    Comp: $172.73k
  • Dr. Krystof Bankiewicz M.D.
    Ph.D., Founder
  • Dr. Guangping Gao Ph.D.
    Founder & Member of Scientific Advisory Board
  • Dr. Mark A. Kay M.D. (Age 65)
    Ph.D., Founder
  • Dr. Phillip D. Zamore Ph.D.
    Founder & Member of Scientific Advisory Board
  • Ms. Robin Swartz (Age 53)
    Chief Operating Officer
  • Mr. Todd Carter Ph.D. (Age 54)
    Chief Scientific Officer
  • Ms. Jacquelyn Fahey Sandell Esq.
    J.D., Chief Legal Officer
  • Ms. Michelle Quinn Smith
    Chief Human Resources Officer














VYGR Stock Analysis - Frequently Asked Questions

Should I buy or sell Voyager Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VYGR shares.
View VYGR analyst ratings
or view top-rated stocks.

What is Voyager Therapeutics' stock price target for 2024?

4 brokers have issued 12-month target prices for Voyager Therapeutics' stock. Their VYGR share price targets range from $14.00 to $18.00. On average, they expect the company's share price to reach $16.00 in the next year. This suggests a possible upside of 66.0% from the stock's current price.
View analysts price targets for VYGR
or view top-rated stocks among Wall Street analysts.

How have VYGR shares performed in 2024?

Voyager Therapeutics' stock was trading at $8.44 at the start of the year. Since then, VYGR shares have increased by 14.2% and is now trading at $9.64.
View the best growth stocks for 2024 here
.

When is Voyager Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VYGR earnings forecast
.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) announced its earnings results on Tuesday, November, 2nd. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.08. The business earned $1.48 million during the quarter, compared to analysts' expectations of $2 million. Voyager Therapeutics had a net margin of 52.93% and a trailing twelve-month return on equity of 63.89%.

What ETF holds Voyager Therapeutics' stock ?

iShares Neuroscience and Healthcare ETF holds 4,243 shares of VYGR stock, representing 0.82% of its portfolio.

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (9.63%), Vanguard Group Inc. (5.75%), Price T Rowe Associates Inc. MD (2.28%), Price T Rowe Associates Inc. MD (2.28%), Dimensional Fund Advisors LP (2.12%) and Federated Hermes Inc. (1.25%). Insiders that own company stock include Alfred Sandrock, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Neurocrine Biosciences Inc, Omar Khwaja, Peter P Pfreundschuh, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter.
View institutional ownership trends
.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VYGR) was last updated on 3/4/2024 by MarketBeat.com Staff